<DOC>
	<DOCNO>NCT01339104</DOCNO>
	<brief_summary>Open label Phase I study Regorafenib evaluate cardiovascular safety , tolerability anti-tumor activity patient advance solid tumor</brief_summary>
	<brief_title>Open Label Regorafenib Study Evaluate Cardiovascular Safety Parameters , Tolerability , Anti-tumor Activity</brief_title>
	<detailed_description />
	<criteria>Male female subject &gt; /= 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate bone marrow , liver , renal function assess follow laboratory requirement conduct within 7 day prior dose : Hemoglobin ( Hb ) &gt; /= 9.0 g/dL , Absolute neutrophil count ( ANC ) &gt; /= 1500/mm³ , Platelet &gt; /= 100,000/mm³ , Total bilirubin &lt; /= 1.5 time upper limit normal ( ULN ) , Alkaline phosphatase &lt; /= 4 x ULN Alanine Aminotransferase ( ALT ) Aspartate Aminotransferase ( AST ) &lt; /= 2.5 time ULN ( &lt; /= 5.0 x ULN subject liver involvement cancer ) , International Normalized Ratio ( INR ) Partial Thromboplastin Time ( PTT ) &lt; 1.5 x ULN , Serum creatinine &lt; /= 1.5 time ULN glomerular filtration rate ( GFR ) &gt; /= 30 ml/min/1.73 m² accord MDRD ( Modified Diet Renal Disease ) abbreviate formula , Lipase &lt; /= 1.5 x ULN Left Ventricular Ejection Fraction ( LVEF ) &gt; /= 50 % assessed Baseline Multigated Acquisition ( MUGA ) scan QTc ( QT correct ) &lt; /= 470 msec Screening Having advanced , refractory disease Life expectancy least 3 month Recovery previous drug/procedurerelated toxicity Common Toxicological Criteria ( CTC ) Grade 0 1 level ( except alopecia ) , baseline precede prior treatment . History cardiac disease : congestive heart failure &gt; New York Heart Association ( NYHA ) Class II ; active coronary artery disease ( unstable angina [ anginal symptom rest ] newonset angina [ begin within last 3 month ] myocardial infarction within past 6 month ) . Uncontrolled hypertension ( failure diastolic blood pressure fall 90 mmHg , despite use &gt; /= 3 antihypertensive drug systolic blood pressure great 150 mmHg ) History know human immunodeficiency virus ( HIV ) infection active hepatitis B C. Subjects serious nonhealing wound , ulcer , bone fracture Subjects arterial venous thrombotic embolic event cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis , pulmonary embolism within 6 month start study medication Persistent proteinuria CTC Grade 3 high ( &gt; 3.5 g/24 hour , measure urine protein/creatinine ratio random urine sample ) Symptomatic metastatic brain meningeal tumor unless subject &gt; 6 month definitive therapy , evidence tumor growth image study within 2 week prior study entry , clinically stable respect tumor time study entry Clinically significant bleeding ( CTC AE Grade 3 high ) within 30 day start study medication . Subjects seizure disorder require anticonvulsant medication History organ allograft</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Cardiovascular safety</keyword>
</DOC>